Key facts
- This page summarizes Michael Kauffman's Form 4 filing for Adicet Bio, Inc. (ACET).
- 6 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 23 Aug 2024, 16:05.
Michael Kauffman - 21 Aug 2024 Form 4 Insider Report for Adicet Bio, Inc. (ACET)
- Reporting relationship
- Director
- Issuer ticker
- ACET
- Reported as of
- 21 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Aug 2024, 16:05:45 UTC
- Prior SEC filing
- 21 Jun 2024
- Next SEC filing
- 27 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nick Harvey, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Kauffman filed Form 4 for Adicet Bio, Inc. (ACET) on 23 Aug 2024.
Change
- Previous filing in this sequence was filed on 21 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACET
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -37,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,000
- Exercise price
- $2.14
- Footnotes
- F1, F2
ACET
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +37,000
- Change %
- Price
- $0.000000
- Shares after
- 37,000
- Date
- 21 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,000
- Exercise price
- $9.39
- Footnotes
- F1, F2
ACET
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -18,500
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,500
- Exercise price
- $2.14
- Footnotes
- F1, F3
ACET
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +18,500
- Change %
- Price
- $0.000000
- Shares after
- 18,500
- Date
- 21 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,500
- Exercise price
- $11.49
- Footnotes
- F1, F3
ACET
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -26,400
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,400
- Exercise price
- $2.14
- Footnotes
- F1, F3
ACET
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +26,400
- Change %
- Price
- $0.000000
- Shares after
- 26,400
- Date
- 21 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,400
- Exercise price
- $5.20
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Michael Kauffman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
Footnote F2
The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
Footnote F3
The shares subject to this option are fully vested and exercisable as of the date hereof.